We are live on ! Find out more
STML

Stemline Therapeutics, Inc.
STML

Delisted

STML was delisted on the 9th of June, 2020.

Back to rankings

Fund managers haven’t disclosed any holdings of STML yet.

STML Hedge Fund Activity: Q2 2020 in Review

0 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q2 2020, worth a combined $0 — down 100% from $194M a quarter earlier.

Sellers outnumbered buyers: 94 funds closed out of STML and 0 opened new positions — a net loss of 94 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Eventide Asset Management, exiting entirely with an estimated $20.1M sold.

  • 0 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q2 2020, down from 94 in Q1 2020.
  • Funds reported $0 of Stemline Therapeutics, Inc. stock for Q2 2020, down 100% quarter-over-quarter.
  • 0 funds opened new Stemline Therapeutics, Inc. positions in Q2 2020 and 94 closed out, a net change of -94 holders.
  • The largest Stemline Therapeutics, Inc. seller in Q2 2020 was Eventide Asset Management, an estimated $20.1M sold.

Based on aggregated 13F filings for Q2 2020.